Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | NCF1 | P14598 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7531114 | 0.99 | KDM4E (0.54) | KDM4EMAPTRAD52NCF1GAA | |
| SCHEMBL24151230 | 0.84 | ADRB2 (0.58) | KDM4EMAPTNCF1GAAKMT2A | |
| SCHEMBL3948439 | 0.82 | NCF1 (0.70) | NCF1HRH3HTR1AHTR1DHTR1B | |
| SCHEMBL3847734 | 0.82 | NCF1 (0.70) | NCF1GAAKMT2AMEN1GLA | |
| SCHEMBL12928129 | 0.82 | NCF1 (0.48) | RAD52NCF1GAAKMT2AMEN1 | |
| SCHEMBL13827009 | 0.82 | NCF1 (0.48) | RAD52NCF1GAAKMT2AMEN1 | |
| SCHEMBL16549300 | 0.82 | GAA (0.53) | MAPTNCF1GAAMAPKAPK2ADRB2 | |
| Hydrochloric Acid SCHEMBL7590361 | 0.81 | NCF1 (0.68) | NCF1HRH3HTR1AHTR1DHTR1B | |
| SCHEMBL10268352 | 0.78 | NCF1 (0.67) | NCF1KMT2AHRH4ADRA2CADRB2 | |
| SCHEMBL30764256 | 0.78 | NCF1 (0.44) | RAD52NCF1GAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3040337-B1 | 2, 6-DI-NITROGEN-CONTAINING SUBSTITUTED PURINE DERIVATIVE, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | ZHEJIANG MED XINCHANG PHARM (CN) | 2019-04-17 | — | — | EP | disclosed |
| US-9718823-B2 | 2, 6-Di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2017-08-01 | — | — | US | disclosed |
| US-9718823-B2 | 2, 6-Di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2017-08-01 | — | — | US | disclosed |
| US-20160207924-A1 | 2, 6-Di-Nitrogen-Containing Substituted Purine Derivative, And Preparation Method, Pharmaceutical Composition And Use Thereof | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2016-07-21 | — | — | US | disclosed |
| US-20160207924-A1 | 2, 6-Di-Nitrogen-Containing Substituted Purine Derivative, And Preparation Method, Pharmaceutical Composition And Use Thereof | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2016-07-21 | — | — | US | disclosed |
| EP-3040337-A1 | 2, 6-DI-NITROGEN-CONTAINING SUBSTITUTED PURINE DERIVATIVE, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015027667-A1 | 2, 6-DI-NITROGEN-CONTAINING SUBSTITUTED PURINE DERIVATIVE, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 浙江医药股份有限公司新昌制药厂 (CN) | 2015-03-05 | — | — | WO | disclosed |
| EP-1450806-B1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB PUBL (SE) | 2009-04-29 | — | — | EP | disclosed |
| EP-1450806-A1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030166663-A1 | Use | BIOVITRUM AB (SE) | 2003-09-04 | — | — | US | disclosed |
| WO-2003039547-A1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| EP-1228066-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032646-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
| EP-1047691-A1 | QUINOLINEPIPERAZINE AND QUINOLINEPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS COMBINED 5-HT1A, 5-HT1B AND 5-HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999031086-A1 | QUINOLINEPIPERAZINE AND QUINOLINEPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS COMBINED 5-HT1A, 5-HT1B AND 5-HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207924-A1 | 2, 6-Di-Nitrogen-Containing Substituted Purine Derivative, And Preparation Method, Pharmaceutical Composition And Use Thereof | NUDT1, PNP, SLC29A2 | KDM4E 3865/4885MAPT 2325/4885RAD52 2295/4885 |
| US-20030166663-A1 | Use | SULT2A1, SULT1A1, SLC5A1 | KDM4E 918/4885MAPT 4806/4885RAD52 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.